ScholarLens Back to search
2014•The Journal of Clinical PsychiatryRequires access

Failed Studies Should Not Be Used to Malign Good Treatments

Patricia L. Gerbarg, Philip R. Muskin, Teodoro Bottiglieri, Richard P. Brown

Open publisher page 3 citations

Abstract

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: The recent double-blind, randomized, placebo-controlled trial of S-adenosylmethionine (SAMe) versus escitalopram in major depressive disorder (MDD) was reported as a failed trial by Mischoulon and colleagues. In intent-to-treat samples, no significant differences were found in response rates: 36% for SAMe, 34% for escitalopram, and 30% for placebo. The remission rates of 28% for SAMe, 28% for escitalopram, and 17% for placebo suggested that both active treatments produced "a more robust †true†effect"(p374) compared to placebo.

About this research paper

What this paper is about

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: The recent double-blind, randomized, placebo-controlled trial of S-adenosylmethionine (SAMe) versus escitalopram in major depressive disorder (MDD) was reported as a failed trial by Mischoulon and colleagues. In intent-to-treat samples, no significant differences were found in response rates: 36% for SAMe, 34% for escitalopram, and 30% for placebo. The remission rates of 28% for SAMe, 28% for escitalopram, and 17% for placebo suggested that both active treatments produced "a more robust †true†effect"(p374) compared to placebo.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: The recent double-blind, randomized, placebo-controlled trial of S-adenosylmethionine (SAMe) versus escitalopram in major depressive disorder (MDD) was reported as a failed trial by Mischoulon and colleagues. In intent-to-treat samples, no significant differences were found in response rates: 36% for SAMe, 34% for escitalopram, and 30% for placebo. The remission rates of 28% for SAMe, 28% for escitalopram, and 17% for placebo suggested that both active treatments produced "a more robust †true†effect"(p374) compared to placebo.

Key concepts: Escitalopram, Placebo, Major depressive disorder, Psychology, Psychiatry, Placebo response, Placebo group, Randomized controlled trial

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Failed Studies Should Not Be Used to Malign Good Treatments — Research Paper | ScholarLens